Item 5. Other Information
Item 5. Other Information
None.
35
Item 6. Exhibits
Exhibit No.
Description
10.1
Executive Employment Agreement, dated as of August 3, 2021, by and between TherapeuticsMD, Inc. and Hugh O’Dowd (1)
10.2
TherapeuticsMD, Inc. Inducement Grant Restricted Stock Unit Agreement, dated as of August 31, 2021, by and between TherapeuticsMD, Inc. and Hugh O’Dowd ( 2 )
10.3
Executive Employment Agreement, dated October 15, 2021, by and between TherapeuticsMD, Inc. and Mark Glickman (3)
10.4
TherapeuticsMD, Inc. Inducement Grant Restricted Stock Unit Agreement, dated October 15, 2021, by and between TherapeuticsMD, Inc. and Mark Glickman (4)
10.5
Amendment to Employment Agreement between TherapeuticsMD, Inc. and James C. D’Arecca, dated October 15, 2021
31.1*
Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a)
31.2*
Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a)
32.1**
Section 1350 Certification of Chief Executive Officer
32.2**
Section 1350 Certification of Chief Financial Officer
101*
Inline XBRL Document Set for the condensed consolidated financial statements and accompanying notes in Part I, Item 1, “Financial Statements” of this Quarterly Report on Form 10-Q
104*
Inline XBRL for the cover page of this Quarterly Report on Form 10-Q, included in the Exhibit 101 Inline XBRL Document Set
*
Filed herewith.
**
Furnished herewith.
(1)
Filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on August 9, 2021 and incorporated herein by reference (File No. 001-00100).
( 2 )
Filed as Exhibit 10.1 to the Company’s Form S-8 filed with the SEC on August 31, 2021 and incorporated herein by reference (File No. 333-259221).
( 3 )
Filed as Exhibit 10.1 to the Company’s Form S-8 filed with the SEC on October 15, 2021 and incorporated herein by reference (File No. 333-260295).
( 4 )
Filed as Exhibit 10.2 to the Company’s Form S-8 filed with the SEC on October 15, 2021 and incorporated herein by reference (File No. . 333-260295).
36
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: November 12, 2021
TherapeuticsMD, Inc.
/s/ Robert G. Finizio
Robert G. Finizio
Chief Executive Officer
(Principal Executive Officer)
/s/ James C. D’Arecca
James C. D’Arecca
Chief Financial Officer
(Principal Financial Officer)
37
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.